Stay connected & subscribe to Rhenovia News Feed
Get English News Feed
A Rhenovia Pharma is a R&D pharmaceutical and biotechnology company created in May 2007.
We are headquartered near the Maison du Technopole in Mulhouse.
It has been founded by an international team highly committed to find new solutions to treat Alzheimer's disease (AD) and other diseases of the central nervous system (CNS).
Rhenovia has the legal form of an SAS. At present, it is mainly funded by the founders and the team.
Dec 2013 - Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director
Nov 2013 - RHEDAR™, a Rhenovia drug candidate to treat Huntington's disease proposed for out-licensing
Nov 2013 - Invited by the European Commission, Rhenovia Pharma unveils the keys to its success at the 2013 SME assembly
Feb 2013 - Press announcement: Rhenovia Pharma recognized as the world leader in biosimulation of the central nervous system
Assessing Numerical Resolution Methods Performance for Kinetic Models of Receptors and Channels
IDENTIFICATION BY BIOSIMULATION OF A NOVEL DRUG CANDIDATE TO TREAT HUNTINGTON’S DISEASE (HD), RHEDAR™
Rhenovia Receives €2.5M to Further Develop Its Biosimulation Platform GEN News Highlights
Newsletter April 2008